Drug Search Results
More Filters [+]

Cixutumumab

Alternative Names: cixutumumab, imc-a12
Latest Update: 2024-04-02
Latest Update Note: Clinical Trial Update

Product Description

A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)

Mechanisms of Action: IGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cixutumumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Adrenocortical Carcinoma|Neurofibrosarcoma|Leiomyosarcoma|Synovial Sarcoma|Hemangiosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Osteosarcoma|Primitive Neuroectodermal Tumors|Gliosarcoma|Liposarcoma|Sarcoma, Ewing|Embryonal Rhabdomyosarcoma|Alveolar Soft Part Sarcoma|Non-Small-Cell Lung Cancer|Alveolar Rhabdomyosarcoma|Adenocarcinoma|Prostate Cancer|Hepatocellular Carcinoma|Pancreatic Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Breast Cancer|Small Cell Lung Cancer|Uveal Melanoma|Liver Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Mesothelioma|Rhabdomyosarcoma|Hepatoblastoma|Retinoblastoma|Wilms Tumor|Bronchiolo-Alveolar Adenocarcinoma|Large Cell Carcinoma|Gastrointestinal Cancer|Peritoneal Cancer|Neuroblastoma|Esophageal Cancer|Soft Tissue Cancer|Kidney Cancer|Embryonal Carcinoma|Colorectal Cancer|Male Breast Cancer

Phase 1: Insulinoma|Oncology Solid Tumor Unspecified|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Carcinoid Tumor|Medullary Carcinoma|Carcinoma, Merkel Cell|Glucagonoma|Islet Cell Carcinoma|Pancreatic Cancer|Paraganglioma|Somatostatinoma|Carotid Body Tumor|Neuroendocrine Tumors|Gastrinoma|Peripheral Neuroectodermal Tumors, Primitive|Sarcoma, Ewing|Malignant Carcinoid Syndrome|Primitive Neuroectodermal Tumors|Pinealoma|Glioma|Thrombocytopenia|Anemia|Hyperglycemia|Neutropenia|Hepatocellular Carcinoma|Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2011-03039

P2

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2018-08-15

NCI-2011-01917

P2

Completed

Small Cell Lung Cancer

2016-11-15

10-C-0146

P2

Completed

Peritoneal Cancer|Mesothelioma

2016-08-13

A Study in Non-Small Cell Lung Cancer

P2

Completed

Squamous Cell Carcinoma

2016-06-10

Recent News Events